Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

Implantable cardioverter defibrillator therapy in a patient with the idiopathic long QT syndrome.

The idiopathic long QT syndrome (LQTS) carries a high mortality in untreated patients. Administration of beta-receptor antagonists is considered the treatment of choice. Data concerning the usefulness of implantable cardioverter-defibrillator (ICD) therapy in this condition are sparse. We report on a 29-year-old female with LQTS who was treated with propranolol, but also underwent implantation of an ICD as a fail-safe therapy. During the next 17 months, the patient was asymptomatic. However, after skipping her propranolol for 3 days, she had several syncopal spells with concomitant device therapy. ICD interrogation revealed a total of 55 nonsustained runs of ventricular tachycardia and 16 sustained episodes that were correctly identified by the device and respectively terminated by the first shock. This case report demonstrates that in selected patients with the LQTS, using ICD therapy as a fail-safe treatment may be life-saving, particularly when compliance to medical therapy is uncertain.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app